[PDF] Top 20 Developments in the Management of Advanced Non Small Cell Lung Cancer

... The first studies for the use of ΤΚΙs as first line agents produced disappointing results. They were performed on patients with NSCLC, without controlling for TKI sensi- tizing EGFR mutations. Seven completed phase II ... See full document

... were no differences between the 250 mg and 500 mg daily doses according to response rates (12% versus 10%), median survival (7 months versus 6 months), and projected 1-year survival (27% versus 24%). Treatment was well ... See full document

... screen in the Ba/F3 cell line with mutant EGFR (L858R, exon 19 deletion with or without T790M). Hereby, they discovered three tertiary mutations in EGFR conferring resistance to one or more third-generation ... See full document

... the management of advanced non-small cell lung cancer (NSCLC), prognosis for these patients remains ...poor. Small molecule epidermal growth factor receptor (EGFR) ... See full document

... a non-tumor specific estimate of cfDNA, it has been argued that this approach is insufficient in order to foresee tumor related events such as progression and ...known advanced lung cancer, we ... See full document

... oral small-molecule EGFR TKI, has been demonstrated to be superior to standard chemo- therapy as first-line and second-line treatment in terms of overall response rate and progression-free survival for ... See full document

... with non-squamous NSCLC, using the single technology appraisal process and based on the Evidence Review Group’s exploratory analysis indicating that the incremental cost- effectiveness ratios (ICERs) for cisplatin ... See full document

... with advanced solid tumors at doses up to 200 mg twice daily, which was determined as the ...progenitor cell sub- sets as well as of plasma soluble VEGFR2 (sVEGFR2) were evaluated as potential biomarkers ... See full document

... Apatinib is a novel small-molecule protein tyrosine kinase (PTK) inhibitor that selectively targets VEGFR-2, which binds all VEGF-A isoforms, VEGF-C, and VEGF-D. The binding of VEGF-A to VEGFR-2 can induce a ... See full document

... In the current study, icotinib re-administration plus apatinib demonstrated an ORR of 11.1%, a DCR of 81.5% and a median PFS of 5.33 months. The high rate of DCR and long period of PFS demonstrated that icotinib ... See full document

... adverse reactions, better tolerance, and significantly lower prices compared with gefitinib and erlotinib. Icotinib has now been included in medical insurance in some cities in the People’s Republic of China. Upon ... See full document

... nonsquamous cell sub- types, and it has been shown that anti-PD-1/PD-L1 therapy may provide differential benefit for different histological ...the Cancer Genome Atlas Research Network showed that ... See full document

... represents about 80% of all lung cancers diagnosed [1]. Most NSCLC patients already present with advanced stages at initial diagnosis, metastasis, and early relapse. Moreover, the prognosis of NSCLC remains ... See full document

... Primary lung cancer is one of the most common malig- nant tumors and is still the leading cause of cancer- related death in many countries [1, ...of lung cancer is increasing every ... See full document

... with advanced lung cancer could vary by the proportion of patients with driver mutations, the proportion receiving targeted therapy, and the proportion with advanced lung ...on ... See full document

... locally advanced, stage IIIB non-small cell lung cancer who had no clinical symptoms of superior vena cava syndrome at the time of ... See full document

... Implementation of NSCLC therapy aims to prolong the survival time, control tumor-related symptoms as well as improve patients ’ quality of life. 5,6 Currently, surgery is the standard of care for resectable, early-stage ... See full document

... other lung cancer driver mutations, these molecular double-hits are rare ...as small interfering RNA silencing of the EML4-Alk fusion in cell lines inhibits cell growth more than 50%, ... See full document

... Lung cancer is a lethal malignancy, however, no serum marker is routinely recommended till ...with advanced lung cancer. Group II: patients with benign lung disease as ...with ... See full document

... interstitial lung disease (patients with chronic, stable, radio- graphic changes who are asymptomatic need not be ...the lung must be completed at least 4 weeks before day 1 with no persistence of any ... See full document